AA
MCID: ALP009
MIFTS: 64

Alopecia Areata (AA)

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Alopecia Areata

MalaCards integrated aliases for Alopecia Areata:

Name: Alopecia Areata 12 76 53 25 29 55 6 44 15 73
Alopecia Circumscripta 53 25
Cazenave's Vitiligo 53 73
Jonston's Alopecia 53 73
Marginal Alopecia 53 73
Celsus' Vitiligo 53 73
Diffuse Alopecia 53 73
Patchy Alopecia 53 6
Alopecia Celsi 53 73
Aa 53 25
Circumscribed Alopecia 12
Alopecia Cicatrisata 53
Pseudopelade 73
Alopecia 73

Classifications:



External Ids:

Disease Ontology 12 DOID:986
ICD10 33 L63 L63.9
ICD9CM 35 704.01
MeSH 44 D000506
SNOMED-CT 68 68225006

Summaries for Alopecia Areata

NIH Rare Diseases : 53 Alopecia areata (AA) is an autoimmune disease in which the immune system mistakenly attacks the hair follicles. In most cases, hair falls out in small, round patches on the scalp. Although uncommon, hair loss can be more extensive in some people and affect other parts of the body. This condition can progress to complete loss of scalp hair (alopecia totalis) or total loss of all body hair (alopecia universalis). Although the exact cause of AA is unknown, roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of the condition. There is no cure or approved therapy for AA; however, some people find that medications approved for other purposes can help regrow hair.

MalaCards based summary : Alopecia Areata, also known as alopecia circumscripta, is related to aplastic anemia and vitiligo-associated multiple autoimmune disease susceptibility 1, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia Areata is TRPS1 (Transcriptional Repressor GATA Binding 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Clobetasol and Acitretin have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and thyroid, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 An autoimmune hypersensitivity disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots.

Genetics Home Reference : 25 Alopecia areata is a common disorder that causes hair loss. "Alopecia" is a Latin term that means baldness, and "areata" refers to the patchy nature of the hair loss that is typically seen with this condition.

Wikipedia : 76 Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all... more...

Related Diseases for Alopecia Areata

Diseases in the Alopecia Areata family:

Alopecia Areata 1 Alopecia Areata 2

Diseases related to Alopecia Areata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 788)
# Related Disease Score Top Affiliating Genes
1 aplastic anemia 32.0 FASLG HLA-A IFNG IL2 TNF
2 vitiligo-associated multiple autoimmune disease susceptibility 1 31.0 AIRE CTLA4 PTPN22
3 psoriasis 30.7 CXCL10 ICAM1 IFNG IL1A IL2 PTPN22
4 dermatitis, atopic 30.7 CXCL10 ICAM1 IFNG IL2 IL2RA TNF
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.7 AIRE CTLA4 IFNG PTPN22
6 arthritis 30.6 IFNG IL1A IL1RN PTPN22 TNF
7 lichen planus 30.5 GZMB ICAM1 IFNG TNF
8 contact dermatitis 30.5 ICAM1 IFNG IL1A TNF
9 autoimmune disease 30.5 AIRE CTLA4 IFNG IL1RN IL2 IL2RA
10 myasthenia gravis 30.4 AIRE CTLA4 IFNG IL2 TNF
11 chronic mucocutaneous candidiasis 30.4 AIRE IFNG IL2RA PTPN22 TNF
12 herpes zoster 30.4 HLA-A IFNG IL2
13 pustulosis of palm and sole 30.4 IL1RN TNF
14 thyroiditis 30.4 CTLA4 FASLG IL2 PTPN22
15 mycosis fungoides 30.3 CTLA4 CXCL10 GZMB IL2 IL2RA
16 chronic graft versus host disease 30.2 IFNG IL1A IL2RA TNF
17 allergic contact dermatitis 30.2 ICAM1 IFNG TNF
18 intermediate uveitis 30.1 IFNG IL2 IL2RA TNF
19 viral infectious disease 30.1 CXCL10 IFNG IL2 TNF
20 colitis 30.1 CTLA4 IFNG IL2 TNF
21 graves' disease 30.1 CTLA4 FASLG ICAM1 IFNG IL2RA PTPN22
22 uveitis 30.0 CTLA4 CXCL10 ICAM1 IFNG IL1A IL2RA
23 lymphopenia 30.0 FASLG IFNG IL2 IL2RA
24 keratoconjunctivitis 30.0 ICAM1 IFNG IL2 TNF
25 cutaneous lupus erythematosus 30.0 GZMB ICAM1 TNF
26 celiac disease 1 30.0 CTLA4 GZMB HLA-A IFNG IL2 PTPN22
27 rheumatoid arthritis 29.9 CTLA4 ICAM1 IFNG IL1A IL1RN IL2
28 periodontal disease 29.8 IL1A IL1RN TNF
29 asthma 29.8 ICAM1 IFNG IL1A IL1RN IL2RA TNF
30 juvenile rheumatoid arthritis 29.8 IL1RN IL2RA TNF
31 periodontitis 29.8 IFNG IL1A TNF
32 inflammatory bowel disease 29.8 CTLA4 CXCL10 ICAM1 IFNG IL1A IL1RN
33 multiple sclerosis 29.8 CTLA4 CXCL10 ICAM1 IFNG IL2 IL2RA
34 aggressive periodontitis 29.8 IL1A IL1RN TNF
35 chorioamnionitis 29.8 IL1A IL1RN TNF
36 lepromatous leprosy 29.7 ICAM1 IFNG IL2 TNF
37 toxic shock syndrome 29.7 IFNG IL2 TNF
38 relapsing-remitting multiple sclerosis 29.7 ICAM1 IFNG TNF
39 interstitial lung disease 29.7 IFNG IL1A TNF
40 mumps 29.7 IFNG IL2 IL2RA TNF
41 diabetes mellitus 29.6 AIRE CTLA4 FASLG HLA-A IFNG IL1A
42 systemic onset juvenile idiopathic arthritis 29.6 IL1RN TNF
43 erythema multiforme 29.6 FASLG GZMB ICAM1 IFNG IL2 TNF
44 pericarditis 29.6 IFNG IL1RN TNF
45 lymphadenitis 29.6 FASLG ICAM1 IFNG TNF
46 spondyloarthropathy 29.6 HLA-A IFNG TNF
47 common variable immunodeficiency 29.6 CTLA4 IFNG IL2 IL2RA TNF
48 temporal arteritis 29.5 IFNG IL1RN PTPN22 TNF
49 graft-versus-host disease 29.5 FASLG GZMB HLA-A IFNG IL1A IL2
50 conjunctivitis 29.5 ICAM1 IFNG IL2

Graphical network of the top 20 diseases related to Alopecia Areata:



Diseases related to Alopecia Areata

Symptoms & Phenotypes for Alopecia Areata

UMLS symptoms related to Alopecia Areata:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia Areata according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 GZMB ICAM1 IL1A IL2 IL2RA TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 FASLG GZMB ICAM1 IL1A IL2 IL2RA

MGI Mouse Phenotypes related to Alopecia Areata:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
2 homeostasis/metabolism MP:0005376 10.25 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
3 cardiovascular system MP:0005385 10.24 CTLA4 CXCL10 FASLG ICAM1 IFNG IL1A
4 immune system MP:0005387 10.21 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
5 digestive/alimentary MP:0005381 10.18 AIRE CTLA4 FASLG ICAM1 IFNG IL2
6 endocrine/exocrine gland MP:0005379 10.16 AIRE CTLA4 FASLG ICAM1 IFNG IL2
7 mortality/aging MP:0010768 9.97 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
8 integument MP:0010771 9.92 CTLA4 FASLG ICAM1 IFNG IL1A IL1RN
9 liver/biliary system MP:0005370 9.8 AIRE CTLA4 FASLG IFNG IL2 PTPN22
10 neoplasm MP:0002006 9.5 AIRE FASLG ICAM1 IFNG IL1A IL2
11 respiratory system MP:0005388 9.28 AIRE CTLA4 FASLG IFNG IL2 IL2RA

Drugs & Therapeutics for Alopecia Areata

Drugs for Alopecia Areata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 497)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3 25122-46-7, 25122-41-2 5311051 32798
2
Acitretin Approved Phase 4 55079-83-9 5284513 6437841
3
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 124-94-7 31307
4
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 38304-91-5 4201
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
7
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Not Applicable 2921-57-5
9
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3 50-28-2 5757
10
Polyestradiol phosphate Approved Phase 4,Phase 3 28014-46-2
11
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
12 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3 979-32-8
13
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
14
Abatacept Approved Phase 4,Phase 2 332348-12-6 10237
15
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
16
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
17
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
18
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5311221 5282380
19
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 99011-02-6 57469
20
Hydroxychloroquine Approved Phase 4 118-42-3 3652
21
Capsaicin Approved Phase 4,Not Applicable 404-86-4 1548943
22 Orange Approved Phase 4,Phase 1,Not Applicable
23
Bimatoprost Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 155206-00-1 5311027
24
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
25
Aminolevulinic acid Approved Phase 4,Phase 3,Not Applicable 106-60-5 137
26
Drospirenone Approved Phase 4 67392-87-4 68873
27 tannic acid Approved Phase 4,Phase 3,Phase 2
28
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2 24280-93-1 446541
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 94-09-7, 1994-09-7 2337
31
Tacrolimus Approved, Investigational Phase 4,Phase 1 104987-11-3 445643 439492
32
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
33
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
34
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
35
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
36
Ketoconazole Approved, Investigational Phase 4 65277-42-1 3823 47576
37
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
38
Levonorgestrel Approved, Investigational Phase 4,Phase 3 17489-40-6, 797-63-7 13109
39
Desogestrel Approved Phase 4 54024-22-5 40973
40
Spironolactone Approved Phase 4,Phase 2 52-01-7, 1952-01-7 5833
41
Apremilast Approved, Investigational Phase 4,Phase 2,Not Applicable 608141-41-9 11561674
42
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
43
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
45
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
46
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
47
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Not Applicable 2920-86-7
48
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 31703
49
Cobalamin Experimental Phase 4 13408-78-1 6438156
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 656)
# Name Status NCT ID Phase Drugs
1 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Unknown status NCT02999737 Phase 4
2 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
3 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
4 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
5 Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
6 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
7 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
8 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed NCT00176943 Phase 4 Aldara Cream 5%
9 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
10 Response of Topical Capsaicin in Alopecia Areata Completed NCT00176969 Phase 4 Capsaicin
11 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
12 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
13 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
14 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
15 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
16 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
17 The Vienna Prograf and Endothelial Progenitor Cell Study Completed NCT00182559 Phase 4 Ciclosporin;Tacrolimus
18 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
19 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4 pazopanib
20 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
21 Intralesional Steroids in the Treatment of Alopecia Areata Recruiting NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
22 Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Recruiting NCT03422640 Phase 4 Apremilast
23 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
24 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
25 Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
26 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
27 Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
28 Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant Active, not recruiting NCT03353012 Phase 4 Etonogestrel Drug Implant;Levonorgestrel Drug Implant
29 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
30 Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
31 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Not yet recruiting NCT03800979 Phase 4 Tofacitinib
32 Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation Not yet recruiting NCT03473600 Phase 4 Triamcinolone acetonide injection
33 Pain Outcomes Following Intralesional Corticosteroid Injections Not yet recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
34 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
35 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
36 Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study Unknown status NCT00746148 Phase 3
37 Reflexology's Effect on Polycystic Ovary Syndrome (PCOS) Unknown status NCT00744510 Phase 3
38 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
39 Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation Unknown status NCT01615757 Phase 3 Ara-c;Ara-c
40 Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Unknown status NCT01671384 Phase 3 Valproate, Levocarnitine;Placebo
41 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
42 A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
43 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
44 The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade Completed NCT02037191 Phase 3 Methotrexate;Placebo
45 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
46 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
47 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
48 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
49 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
50 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg

Search NIH Clinical Center for Alopecia Areata

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: alopecia areata

Genetic Tests for Alopecia Areata

Genetic tests related to Alopecia Areata:

# Genetic test Affiliating Genes
1 Alopecia Areata 29

Anatomical Context for Alopecia Areata

MalaCards organs/tissues related to Alopecia Areata:

41
Skin, T Cells, Thyroid, Testes, Bone, Kidney, Lung

Publications for Alopecia Areata

Articles related to Alopecia Areata:

(show top 50) (show all 1249)
# Title Authors Year
1
Alopecia areata after dupilumab for atopic dermatitis. ( 29387767 )
2018
2
Alopecia areata. ( 29908825 )
2018
3
Chronological clinicopathological characterization of rapidly progressive alopecia areata resistant to multiple i.v. corticosteroid pulse therapies: An implication for improving the efficacy. ( 29963718 )
2018
4
Alopecia Areata-like Hair Loss Accompanying Toxic Epidermal Necrolysis. ( 29856464 )
2018
5
Coexistence of Dermatomyositis and Alopecia Areata: Insight into Pathogenesis. ( 29854645 )
2018
6
An investigation of vitamin D status in alopecia areata. ( 29869122 )
2018
7
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch Type Alopecia Areata, Totalis and Universalis. ( 29452121 )
2018
8
Fibroblast cell-based therapy prevents induction of alopecia areata in an experimental model. ( 29871523 )
2018
9
Annular Alopecia Areata: A Morphologically Rare Variant. ( 29440858 )
2018
10
Quality of life in mild and severe alopecia areata patients. ( 29872683 )
2018
11
The risk of alopecia areata and other related autoimmune diseases in patients with sleep disorders: a Korean population-based retrospective cohort study. ( 29955877 )
2018
12
Alopecia Areata: The Clinical Situation. ( 29273111 )
2018
13
Spontaneous hair regrowth in eight patients with severe alopecia areata. ( 29931820 )
2018
14
Big Data Reveal Insights into Alopecia Areata Comorbidities. ( 29273109 )
2018
15
Immunoregulatory Effects of Myeloid-Derived Suppressor Cell Exosomes in Mouse Model of Autoimmune Alopecia Areata. ( 29951053 )
2018
16
Hemorrhagic Ischemic Retinal Vasculitis and Alopecia Areata as a Manifestation of HLA-B27. ( 29304269 )
2018
17
Applying the Common Sense Model to predicting quality of life in alopecia areata: The role of illness perceptions and coping strategies. ( 29355049 )
2018
18
Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO). ( 29874239 )
2018
19
Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children, and their families. ( 29425723 )
2018
20
Cytokine Targeted Therapeutics forA Alopecia Areata: Lessons fromA Atopic Dermatitis and OtherA Inflammatory Skin Diseases. ( 29273110 )
2018
21
Genetic variant association of PTPN22, CTLA4, IL2RA, as well as HLA frequencies in susceptibility to alopecia areata. ( 29979892 )
2018
22
Childhood alopecia areata-Data from the National Alopecia Areata Registry. ( 29334143 )
2018
23
Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29. ( 29853767 )
2018
24
Localized atrophy with surrounding hair growth in a case of alopecia areata treated with intralesional steroids, using a needle-less injector. ( 29956680 )
2018
25
When your patient's parent asks: "My child's alopecia areata is not getting better. Should he or she get tested for celiac disease?" ( 29797748 )
2018
26
One of the best treatments for alopecia areata remains unpublished. ( 29878313 )
2018
27
TNF-I+ -308G/A gene polymorphism in bullous pemphigoid and alopecia areata. ( 29843231 )
2018
28
Development of Frontal Fibrosing Alopecia with a History of Alopecia Areata. ( 29440856 )
2018
29
Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study. ( 29442292 )
2018
30
Genetic analysis of interleukin 18 gene polymorphisms in alopecia areata. ( 29349811 )
2018
31
Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. ( 29754888 )
2018
32
Alopecia areata and the gut-the link opens up for novel therapeutic interventions. ( 29808708 )
2018
33
Do Prolactin and its Receptor Play a Role in Alopecia Areata? ( 29937561 )
2018
34
Nail changes in alopecia areata: an update and review. ( 29318582 )
2018
35
Reply to: "Tofacitinib for the treatment of severe alopecia areata and variants". ( 29332724 )
2018
36
Distinguishing immunohistochemical features of alopecia areata from androgenic alopecia. ( 29790258 )
2018
37
Differential proteomics of lesional vs. non-lesional biopsies revealed non-immune mechanisms of alopecia areata. ( 29323127 )
2018
38
Is there an association of ABO blood groups and Rhesus factor with alopecia areata? ( 29336112 )
2018
39
Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis. ( 29679494 )
2018
40
Polymorphism of FAS and FAS Ligand Genes in Alopecia Areata: A Case-control Study in Egyptian Population. ( 29937558 )
2018
41
Alopecia Areata and Habit Tic Deformities. ( 30410907 )
2018
42
Treatment of alopecia areata: An Australian expert consensus statement. ( 30411329 )
2018
43
A clinical and immunological study of phototoxic regimen of ultraviolet A for treatment of alopecia areata: A randomized controlled clinical trial. ( 30411986 )
2018
44
Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes. ( 30417059 )
2018
45
A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. ( 30417279 )
2018
46
Psychosomatic aspects of alopecia areata. ( 30446192 )
2018
47
Screening of thyroid function and autoantibodies in patients with alopecia areata: A systematic review and meta-analysis. ( 30447313 )
2018
48
Drugs with a stigma: thoughts regarding a recent publication, "One of the Best Treatments for Alopecia Areata Remains Unpublished". ( 30460988 )
2018
49
Living with alopecia areata: An online qualitative survey study. ( 30501016 )
2018
50
Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. ( 30502414 )
2018

Variations for Alopecia Areata

ClinVar genetic disease variations for Alopecia Areata:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TRPS1 NM_014112.4(TRPS1): c.2794G> A (p.Ala932Thr) single nucleotide variant Pathogenic/Likely pathogenic rs1057518972 GRCh38 Chromosome 8, 115418359: 115418359
2 TRPS1 NM_014112.4(TRPS1): c.2794G> A (p.Ala932Thr) single nucleotide variant Pathogenic/Likely pathogenic rs1057518972 GRCh37 Chromosome 8, 116430587: 116430587
3 EMILIN2; LPIN2; METTL4; MYL12A; MYL12B; MYOM1; NDC80; SMCHD1; TGIF1 GRCh37/hg19 18p11.32-11.31(chr18: 1345040-3479168) copy number loss Uncertain significance GRCh37 Chromosome 18, 1345040: 3479168

Expression for Alopecia Areata

Search GEO for disease gene expression data for Alopecia Areata.

Pathways for Alopecia Areata

Pathways related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CTLA4 CXCL10 FASLG HLA-A ICAM1 IFNG
2
Show member pathways
13.36 CXCL10 FASLG HLA-A ICAM1 IFNG IL1A
3
Show member pathways
13.29 CXCL10 FASLG IL1A IL2 IL2RA PTPN22
4
Show member pathways
12.71 CXCL10 FASLG HLA-A ICAM1 IFNG IL1A
5
Show member pathways
12.59 IFNG IL1A IL2 IL2RA TNF
6
Show member pathways
12.59 CTLA4 FASLG GZMB HLA-A ICAM1 IFNG
7
Show member pathways
12.42 CTLA4 IFNG IL1A IL2 TNF
8 12.41 HLA-A ICAM1 IL2 IL2RA TNF
9
Show member pathways
12.4 FASLG GZMB HLA-A ICAM1 IFNG IL2
10
Show member pathways
12.32 ICAM1 IFNG IL2 TNF
11 12.28 CXCL10 HLA-A ICAM1 TNF
12
Show member pathways
12.27 HLA-A IFNG IL1A IL2 IL2RA TNF
13
Show member pathways
12.25 FASLG GZMB IL1A TNF
14
Show member pathways
12.21 FASLG IFNG IL1A TNF
15
Show member pathways
12.18 CXCL10 FASLG IFNG TNF
16 12.09 ICAM1 IFNG IL1A TNF
17
Show member pathways
12.08 ICAM1 IFNG IL1A IL2 IL2RA
18 11.99 IFNG IL2 IL2RA TNF
19 11.99 CXCL10 ICAM1 IFNG IL1A IL2 TNF
20 11.98 FASLG ICAM1 IL1A TNF
21
Show member pathways
11.93 FASLG GZMB HLA-A IFNG IL2 IL2RA
22 11.89 CTLA4 ICAM1 IFNG IL1A TNF
23 11.87 ICAM1 IL1A TNF
24 11.86 IL1A IL2RA TNF
25 11.84 CTLA4 CXCL10 FASLG GZMB IFNG IL1RN
26 11.81 GZMB IFNG IL2 IL2RA TNF
27 11.78 ICAM1 IFNG IL2
28 11.74 CXCL10 IFNG IL1RN IL2 TNF
29 11.73 IFNG IL2 TNF
30
Show member pathways
11.68 FASLG IL2 IL2RA
31
Show member pathways
11.67 ICAM1 IFNG IL1A IL2 TNF
32
Show member pathways
11.61 CTLA4 FASLG IFNG IL2 IL2RA TNF
33 11.58 FASLG IFNG IL2 TNF
34 11.54 ICAM1 IFNG TNF
35 11.54 CXCL10 ICAM1 IL1A IL1RN TNF
36 11.52 IFNG IL2 TNF
37 11.52 FASLG IFNG IL1A TNF
38 11.49 IFNG IL2 IL2RA
39 11.47 FASLG ICAM1 IFNG
40 11.4 FASLG ICAM1 IFNG TNF
41 11.38 CXCL10 ICAM1 IFNG
42 11.33 IFNG IL2 IL2RA
43 11.29 IFNG IL1A IL2 TNF
44
Show member pathways
11.29 FASLG GZMB HLA-A IFNG IL2 IL2RA
45 11.24 IFNG IL2 IL2RA
46 11.22 CXCL10 FASLG IL1A IL2 TNF
47 11 CXCL10 FASLG IL1A IL2 TNF
48 10.91 ICAM1 TNF

GO Terms for Alopecia Areata

Cellular components related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CXCL10 FASLG ICAM1 IFNG IL1A IL1RN
2 external side of plasma membrane GO:0009897 9.1 CTLA4 CXCL10 FASLG ICAM1 IL2RA TNF

Biological processes related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.93 CTLA4 HLA-A IL2 IL2RA PTPN22 ULBP3
2 response to lipopolysaccharide GO:0032496 9.83 CXCL10 FASLG ICAM1 PTPN22
3 cellular response to lipopolysaccharide GO:0071222 9.81 CXCL10 ICAM1 IL1RN TNF
4 regulation of signaling receptor activity GO:0010469 9.8 CXCL10 FASLG IFNG IL1A IL1RN IL2
5 interferon-gamma-mediated signaling pathway GO:0060333 9.75 HLA-A ICAM1 IFNG
6 humoral immune response GO:0006959 9.74 AIRE IFNG TNF
7 extrinsic apoptotic signaling pathway GO:0097191 9.67 FASLG IFNG TNF
8 positive regulation of nitric oxide biosynthetic process GO:0045429 9.65 ICAM1 IFNG TNF
9 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.6 IFNG TNF
10 negative regulation of immune response GO:0050777 9.59 CTLA4 IL2RA
11 interleukin-2-mediated signaling pathway GO:0038110 9.58 IL2 IL2RA
12 necroptotic signaling pathway GO:0097527 9.56 FASLG TNF
13 cytokine-mediated signaling pathway GO:0019221 9.56 CXCL10 FASLG ICAM1 IL1A IL1RN IL2
14 negative regulation of lymphocyte proliferation GO:0050672 9.55 IL2 IL2RA
15 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.54 ICAM1 TNF
16 regulation of regulatory T cell differentiation GO:0045589 9.46 CTLA4 IFNG IL2 IL2RA
17 chronic inflammatory response to antigenic stimulus GO:0002439 9.43 IL1RN TNF
18 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.4 IFNG TNF
19 immune response GO:0006955 9.4 AIRE CTLA4 CXCL10 FASLG HLA-A IFNG
20 regulation of T cell homeostatic proliferation GO:0046013 9.37 IL2 IL2RA
21 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 IFNG TNF

Molecular functions related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 AIRE CTLA4 CXCL10 FASLG GZMB HLA-A
2 cytokine activity GO:0005125 9.17 CXCL10 FASLG IFNG IL1A IL1RN IL2
3 interleukin-1 receptor binding GO:0005149 9.16 IL1A IL1RN

Sources for Alopecia Areata

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....